molgramostim
molgramostim: developed by 1 company · 2 clinical trials tracked.
molgramostim evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could molgramostim → SVRA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Savara Inc (SVRA) Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 |
Clinical Trials (2)
An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Primary endpoint: DLCO
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Primary endpoint: Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
Frequently asked questions
Who is developing molgramostim?
molgramostim is being developed by Savara Inc.
How many clinical trials involve molgramostim?
BioSniper tracks 2 clinical trials involving molgramostim.